Direct Measurement of Lipase Inhibition by Orlistat Using a Dissolution Linked In Vitro Assay
نویسندگان
چکیده
PURPOSE To develop a bio-assay that would be able to directly test gastrointestinal and/or dissolution samples to determine lipase activity and inhibition by Orlistat. METHODS Enzyme assays were performed with porcine pancreatic lipase and para-Nitrophenyl Palmitate (pNPP) in pH 8.0 reaction buffer at 37°C. Substrate hydrolysis was monitored by absorbance changes at 410 nm. The dissolution of two Orlistat formulations was tested with a USP II apparatus. Samples were HPLC analyzed to determine release profile in addition to being diluted and directly assayed for inhibitory effect. RESULTS The lipase-pNPP system demonstrates linearity and Michalis-Menten kinetics with a Km=2.7 ± 0.2 μM and Kcat = 0.019 s-1. Orlistat showed highly potent and time dependent inhibition with 5 ng/ml effecting 50% activity after 5 minutes in the Lipase-pNPP system. Dissolution studies showed a correlation of the drug release profile to the inhibitory effect of dissolution samples in the assay. CONCLUSIONS The lipase-pNPP method can be used as an in vitro assay to monitor orlistat inhibition from drug release or dissolution samples.
منابع مشابه
Pharmacodynamic testing and new validated HPLC method to assess the interchangeability between multi-source orlistat capsules
Background Orlistat is an irreversible inhibitor of the lipase enzyme that prevents trigylcerides from being digested, thereby inhibiting triglyceride hydrolysis and absorption. The resultant reduced calorie uptake enables a positive effect on weight control. Systemic absorption of the drug is, therefore, not necessary for its mode of action. An alternative in vitro study (pharmacodynamic) has ...
متن کاملInhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers.
The inhibition of digestive lipases by the antiobesity drug Orlistat along with lipolysis levels and fecal fat excretion were measured in healthy humans. Orlistat was found to be a powerful gastric lipase inhibitor, achieving 46.6--91.4% enzyme inhibition and thus greatly reducing gastric lipolysis of solid and liquid meals (11--33% of respective controls). Gastric lipase inhibition by Orlistat...
متن کاملChem. Pharm. Bull. 55(2) 251—254 (2007)
Orlistat (Xenical) (Fig. 1), a highly lipophilic tetrahydro derivative of lipstatin, is an inhibitor of gastric and pancreatic lipases required for the hydrolysis of dietary fat (triacylglycerols) in the gastrointestinal tract into free fatty acids and monoacylglycerols. A major contributing factor to the development and maintenance of obesity is excessive intake of dietary triglycerides. Inhib...
متن کاملInhibition of lipase activity and lipolysis in rat islets reduces insulin secretion.
Lipids may serve as coupling factors in K(ATP)-independent glucose sensing in beta-cells. We have previously demonstrated that beta-cells harbor lipase activities, one of which is the hormone-sensitive lipase. Whether beta-cell lipases are critical for glucose-stimulated insulin secretion (GSIS) by providing lipid-derived signals from endogenous lipids is unknown. Therefore, using a lipase inhi...
متن کاملSelection of orlistat as a potential inhibitor for lipase from Candida species
Infections caused by Candida species manifest in a number of diseases, including candidemia, vulvovaginal candidiasis, endocarditis, and peritonitis. Candida species have been reported to possess lipolytic activity due to the secretion of lipolytic enzymes such as esterases, lipases and phospholipases. Extra-cellular hydrolytic enzymes seem to play an important role in Candida overgrowth. Candi...
متن کامل